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CHAPTER 1: Introduction 
1.1 Chronic Kidney Disease (CKD) 
Chronic Kidney Disease (CKD) is a global epidemic which has become a huge burden to 
the healthcare system in the USA and countries worldwide.  It has gained the global 
attention due to the rapid increase in prevalence, high cost in treatments, high risk 
associated with Cardiovascular disease (CVD) and need of effective therapies to prevent 
disease progression [1]. The National Kidney Foundation (NKF) reports that CKD affects 
approximately 10-13% of the world population and causes millions of deaths each year [2]. 
It is reported that among people aged from 65 to 74, every one in five men and one in four 
women suffers from CKD worldwide.  According to NKF, CKD was the 27th cause of total 
number of deaths worldwide in 1990, but rose to 18th by 2010, indicating a high movement 
up the list. This high movement was only second to that of HIV and AIDS [3]. 
Among world CKD population, over 2 million receive treatment for CKD either through 
dialysis or kidney transplantation [4]. In the US, treatments for CKD utilized 6.7% of total 
medicare budget in 2010 and the cost is likely to exceed  $ 48 billion per year [2, 3]. In 
China, the estimated cost for treatment for next decade is over $ 558 billion, whereas in 
Australia the estimated cost until 2020 is $ 12 billion [2]. The cost of CKD treatment in the 
UK exceeds the combined cost of skin, lung, breast and colon cancer treatments [2]. 
Furthermore, in Uruguay the annual cost of dialysis is nearly $ 23 million, which is 30% 
of the budget for National Resources Fund for special therapies [2]. In middle income 
countries, most CKD patients are unable to afford dialysis or kidney transplantation, which 
leads to death of over 1 million people annually due to untreated kidney failure in those 
countries [4]. In developing countries, the number of CKD patients is estimated to increase 
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due to the increasing number of elderly population [3]. Therefore, CKD has become a huge 
financial burden to a country’s economy as well as to the patient.  
1.1.1 Stages of CKD 
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KIDOQI) 
guidelines characterize CKD into 5 stages, based on Glomerular Filtration Rate (Table 1.1) 
[5]. According to KIDOQI guidelines CKD is defined as kidney damage of 3 or more 
months duration caused by structural or functional abnormalities with or without a 
decreased GFR. Chronic kidney disease is also defined as the presence of kidney damage 
or GFR less than 60 mL/min/1.73 m2 for 3 months or longer, irrespective of cause [6]. 
Table 1.1: Stages of CKD  
 
                                  Source: United States Renal Data System [5] 
GFR at the stage 1 is >90 ml/min/1.73 m2. At this stage kidneys have about 90-100% 
functionality and this stage can be determined using routine laboratory measurements [7]. 
Stage 2 is also known as mild CKD and at this stage kidneys have 60-89% functionality 
[7]. These patients may be asymptomatic but may have high blood pressure, urine 
abnormalities and normal or slightly elevated serum creatinine levels. Since early stages 
(stage 1-2) can be asymptomatic, development of CKD can only be determined using lab 
tests such as hemoglobin test, urine test for albumin and blood test for serum creatinine [7].  
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Decrease in hemoglobin level indicates decrease in erythropoietin production, which 
occurs due to altered kidney function. Presence of albumin in the urine or 
microalbuminuria, is another early sign of kidney disease [7]. 
If the disease progress to stage 3 and 4, patients may have elevated serum creatinine level 
with 30-59% and 15.29% kidney functionality respectively [9]. At these stages, all organs 
are affected with evident complications including anemia, fatigue, decreasing appetite with 
progressive malnutrition, abnormalities in calcium and phosphorus level.  Progression to 
stage 5 causes kidney function to less than 15% and leads to accumulation of toxins [7]. 
Patients experience loss of urine production and are subjected to severe life threatening 
complications such as difficulty in breathing and chest pain due to fluid retention, severe 
weaknesses, coma and high level of potassium which could affect function of the heart [7]. 
This stage is also known as kidney failure or End Stage Renal Disease (ESRD) and these 
patients need dialysis or renal transplant to survive. 
1.2 Cardiovascular diseases (CVD) in CKD population 
CKD is a major risk factor for CVD and is one of the leading cause of death in CKD. Most 
CKD patients die due to CVD even before reaching ESRD [5]. According to United States 
Renal Data System (USRDS), CVD causes more than half of deaths with known causes in 
ESRD patients [5]. The two major CVD events that occur in ESRD patients are 
atherosclerotic heart disease (ATHD) and congestive heart failure (CHF). In CKD patients 
increased levels of oxidative stress, inflammation, atherogenic oxidation-prone 
lipoproteins and small dense LDL particles and qualitatively dysfunctional HDL particles 
are believed to accelerate atherosclerosis. 
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1.2.1 Atherosclerosis  
Atherosclerosis consists of series of events that occur in the arterial wall, which leads to 
narrowing of arteries through formation of a fatty streak. This process initiates as a result 
of endothelial dysfunction that occurs due to prolonged exposure to hypertension, 
hyperlipidemia, toxins or smoking which can activate endothelial cells [8]. Activated 
endothelial cells secrete vasoconstrictor factors which cause constriction of arteries, factors 
that affect growth and differentiation of vascular smooth muscle cells and expression of  
cellular adhesion molecules [9]. Through these adhesion molecules, monocytes are 
attracted and attached to the endothelial surface and enter the intima, where they 
differentiated into macrophages. These macrophages engulf oxidized LDL which have 
entered the intima via endothelial injury, and become foam cells. 
As this process continues, foam cells secrete growth factors that stimulate migration of 
smooth muscle cells into the intima. These smooth muscle cells interact with foam cells to 
form fatty streak, which is then converted to advanced lesions. Although initial stages such 
as foam cell formation can be reversible, prolonged exposure to risk factors promote 
formation of an atheromatous plaque, that can protrude into the lumen, leading to 
narrowing the artery [9, 10] (Figure 1.1).  
5 
 
 
 
 
                                      Figure 1.1: Formation of atheromatous plaque 
                                (Source: Pathophysiology of Coronary Artery Disease [10]) 
1.2.2 Causes of Atherosclerosis 
Oxidative stress 
Reactive oxygen species (ROS) such as superoxide and peroxide radicals are formed 
during energy production in the cells by mitochondria. In this process, free electrons are 
transported through electron transport chain to its final acceptor, molecular oxygen. 
However, some electrons may escape the chain, forming ROS such as superoxide radicals 
and peroxide radicals [11, 12]. The level of ROS in the body is balanced by the body’s 
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antioxidant level and as the level of ROS over anti-oxidant level increases, it causes 
oxidative stress. ROS are highly reactive and can rapidly interact with DNA, proteins and 
lipids in the cells. Unsaturated lipids such as polyunsaturated fatty acids (PUFA) and 
monounsaturated fatty acids (MUFA) which present in cell membranes, neurons and LDL 
particles can be readily oxidized by ROS. Lipid radicals and peroxyl radicals formed by 
this process are highly reactive and can produce more free radicals via interaction with 
other molecules and cellular compartments (Figure 1.2). Thus, increased oxidative stress 
in the body can increase the level of oxidized LDL in plasma which can promote 
atherosclerosis.  
 
                                               Figure 1.2: Lipid peroxidation   
                                                   (Source: Jayasena et al [12]) 
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Inflammation 
Inflammation participates in atherosclerosis from its early stages. Diets  high in saturated 
fat, hypercholesterolemia, obesity, hyperglycemia, insulin resistance, hypertension, and 
smoking, release pro-inflammatory signals which stimulate arterial cells to produce 
adhesion molecules, that initiate early stages in atherosclerosis [13, 14]. Inflammation is 
known to cause qualitative alterations in LDL particles, which make them highly 
susceptible for oxidation [13]. A higher level of oxidized LDL in the plasma, is known to 
stimulate NFκB pathway, that triggers the production of pro-inflammatory cytokines which  
promotes foam cell formation [13].  Hyperglycemic conditions seen in type-2 diabetes is 
known to increase the production of advanced glycation end products (AGE) which have 
pro-inflammatory properties and stimulate pro-inflammatory cytokines production from 
adipose tissue [13, 14]. In addition, decreased plasma HDL level and anti-oxidant enzymes 
associated with HDL such as paraoxonases, may also promote inflammation. 
Altered lipid metabolism 
One of the leading causes of atherosclerosis is abnormalities in lipid metabolism. Elevated 
small dense LDL particle level, lipoprotein (a) (Lp-a), decreased endothelium bound LPL, 
upregulated HMG-CoA reductase and Acyl-Co A: cholesterolacyltransferase (ACAT) 
activity are reported to promote atherosclerosis  [8]. Small dense LDL particles are 
considered to be a marker for carotid atherosclerosis as they can enter the arterial intima 
through infiltrating the vessel wall [8]. While remain trapped inside the intima, small dense 
LDL are highly susceptible to oxidative modification which can promote foam cell 
formation [8]. 
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Lp-a is a modified lipoprotein which is degraded by kidney. Therefore, in CKD, Lp-a level 
may increase and accumulate in the atherosclerotic lesions. As a result, elevated level of 
Lp-a is considered as an independent risk factor for CVD in CKD patients. Also in CKD 
patients, decreased endothelium bound lipoprotein lipase (LPL) levels are also observed 
which can decrease the clearance of LDL and increase accumulation of LDL in blood [15]. 
These processes increase plasma LDL level, which triggers LDL oxidation and foam cell 
formation, in the presence of high oxidative stress. In addition, CKD impairs metabolism 
of high density lipoproteins (HDL) and reverse cholesterol transport pathway (RCT), 
which play critical roles in removing excess cholesterol from peripheral tissues. 
1.3 Reverse Cholesterol Transport (RCT) 
Cholesterol homeostasis in the body is maintained by balancing plasma cholesterol inflow 
to plasma cholesterol outflow. In cholesterol metabolism, peripheral cells receive 
cholesterol through apo B containing lipoproteins such as LDL, which are enriched with 
cholesterol derived from either diet or endogenous synthesis [15]. Excess cholesterol from 
peripheral tissues including arterial wall, are removed by a RCT (Figure 1.3)  [15, 16]. 
RCT can be mainly divided into several steps namely,  
(1) cholesterol efflux from macrophages  
(2) transport of cholesterol in to plasma  
(3) uptake by the liver and  
(4) excretion from the body   
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Figure 1.3 Reverse Cholesterol Transport 
(Source: Gutstein et al [16]) 
1.3.1 Cholesterol efflux  
Cholesterol efflux is first step in RCT and involves up taking oxidized cholesterol in the 
arterial intima, into the macrophages and releasing excess cholesterol into HDL particles. 
Altered cholesterol efflux causes accumulation of excess cholesterol in macrophages, 
leading to foam cell formation which initiates atherosclerosis [17, 18].  
The uptake of modified LDL occurs through cholesterol influx receptors such as CD 36 
and SRA1. These two receptors are known to be 90% responsible for uptake of oxidized 
cholesterol into macrophages [19]. Once taken into macrophages, oxidized LDL are 
catabolized in the lysosomes in the macrophages. Cholesterol esters in LDL particles are 
then broken down to free cholesterol and fatty acids by lysosomal acid lipase (LAL) [19]. 
Free cholesterol is then converted to cholesterol esters by acyl coenzyme A: cholesterl 
acyltransferase (ACAT 1) in the endoplasmic reticulum (ER) in the macrophage. A 
secondary hydrolysis of cholesterol esters to cholesterol takes place through neutral 
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cholesteryl ester hydrolases, and free cholesterol liberated are effluxed from macrophages 
through cholesterol ATP-binding cassette (ABC) transporters ABCA1 and ABCG1 and 
scavenger receptor SR-BI [8, 20].  Free cholesterol is mainly accepted from ABCG1 and 
SRB1 into large mature HDL (HDL-2) particles whereas Apo-A1 and small nascent HDL 
(HDL-3) particles are the main acceptors for free cholesterol from ABCA1 [8].  
1.3.2 Transporting cholesterol by HDL to liver 
Upon receiving cholesterol into small nascent HDL particles (HDL-3), HDL-3 activates 
lecithin-cholesterol acyltransferase (LCAT), which is an enzyme that converts cholesterol 
into cholesterol esters. This clears the surface space in small nascent HDL (HDL-3) particle 
to accept more free cholesterol and convert it into much larger spherical HDL (HDL-2) 
particles [8]. Cholesterol esters in HDL-2 particles are then exchanged to triglycerides in 
LDL/VLDL particles through Cholesteryl Ester Transfer Protein (CETP).  HDL-2 particles 
rich with cholesterol and triglycerides are then taken up by Scavenger receptors class B 
type 1 (SRB1) which also present in hepatocytes in liver. In the liver, cholesterol 
transported by HDL-2 is de-esterified and secreted into the bile and excrete with feces.  
In CKD, RCT is affected at several stages. Patients with CKD are reported to have 
significantly low plasma levels of cholesterol acceptors such as Apo-AI and HDL level in 
the plasma [8]. The low levels of HDL in these patients can be attributed to higher level of 
CETP [8]. CKD patients also known to have deficiency and reduced function of LCAT 
which impairs conversion of small dense HDL-3 into larger HDL-2. More importantly, 
HDL-3 are mainly degraded by the kidney [16]. Thus, in CKD accumulation of HDL-3 
which has proinflammatory and pro-oxidative properties may occur. On the other hand, 
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due to reduced LCAT activity, CKD may reduce HDL-2 with anti-inflammatory and anti-
oxidant properties [8]. Therefore, reduced HDL level in CKD, may increase the risk for 
atherosclerosis. 
Although an increase in plasma HDL is considered to be atheroprotective, it doesn’t 
necessarily reflect functional properties of HDL [8]. Dysfunctional HDL, even with a 
higher plasma level, may not uptake excess cholesterol, leading to a decrease in clearance 
of excess cholesterol from the body as bile. Therefore, a higher level of plasma HDL may 
not necessarily indicate protective effects from CVD [17]. Since cholesterol efflux require 
functional HDL, which can accept and deliver cholesterol, recent research suggests that 
cholesterol efflux, is a better predictor for CVD risk [17], compared to plasma HDL level. 
It has been suggested that an increased level of cholesterol efflux indicates reduced risk 
and protective effects from CVD and vice versa. Thus, current research focus on therapies 
which improve cholesterol efflux, as a prevention strategy for CVD.  
1.3.3 Effect of PPAR-γ on cholesterol efflux 
PPAR-γ acts as a key regulator of cholesterol influx genes such as SRA1, CD 36 and efflux 
genes such as ABCA1, ABCG1 and SRB1 [20-23]. Increased expression of PPAR-γ is 
known to increase an influx gene, CD 36, while decreasing the expression of another influx 
gene, SRA1 causing no net influx into the macrophages[22, 24, 25]. In addition, PPAR-γ 
is known to increase the expression of efflux genes such as ABCA1, ABCG1 and SRB1 
[20]. Therefore, as a net effect, induction of PPAR-γ is believed to increase the net 
cholesterol efflux from the macrophages [21, 22, 24, 25]. Induction of ABCA1 and ABCG1 
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through PPAR-γ is known to occur through the induction of another gene, LXR-α, which 
is downstream to PPAR-γ but upstream to ABCA1 and ABCG1 (figure 1.4)[21] . 
                 
             Figure 1.4: Effects of PPAR-γ on cholesterol influx and efflux genes 
(Source: Duval et al [21]) 
Therefore, apart from dysfunctional HDL, altered expression of these genes can also lead 
to reduced cholesterol efflux. 
Due to the interaction of PPAR-γ with influx and efflux genes, agents that can induce the 
expression of PPAR-γ can increase net cholesterol efflux leading to reduction in foam cell 
formation. Several research studies have reported the effect of wide variety of bioactive 
compounds and commercially available drugs as PPAR-γ agonists, in increasing 
cholesterol efflux [20, 24-28]. Anti-diabetic thiazolidinedione (TZD) drugs such as 
Troglitazone, have been shown to reduce foam cell formation through modulating PPAR-
γ [24, 25]. Treatment with murine macrophages with TZD, induced PPAR-γ expression 
while down regulating SRA1 and upregulating CD 36, thereby causing no net effect on 
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cholesterol accumulation [24, 25]. Propofol, a phenolic derivative, was shown to increase 
SRB1 expression and ABCA1 expression through PPAR-γ-LXR-α pathway in THP-1 
macrophages [27].  
Due to the potential side effects associated with commercially available drugs, use of 
naturally occurring bioactive compounds in disease prevention and management has 
become a main focus of nutrition research. Several studies have reported the effect of 
bioactive compounds in cholesterol efflux [26, 29-32]. Ferrulic acid found in coffee, has 
been shown to increase cholesterol efflux via upregulation of SRB1 and ABCG1 mRNA 
and protein level in THP-1 human macrophages [33]. Resveratrol found in grapes, berries 
and walnuts was shown to increase LXR-α, ABCA1, ABCG1 and SRB1 mRNA expression 
level in THP-1 human macrophages[31]. In the same study, it was shown that treatment 
with resveratrol increased cholesterol efflux and suppressed foam cell formation.  
Resveratrol has also been shown to increase cholesterol efflux via an ABCA1- dependent 
manner and reduced cholesterol influx in J774A.1 macrophages[29]. In THP-1 
macrophages, resveratrol increased ABCA1 expression via induction of LXR-α and 
reduced the expression of influx gene, SRA1 [34].   
In a study performed with 13-Hydroxy Linolenic acid it was shown that Linolenic acid 
increases Apo-A1 mediated cholesterol efflux while increasing ABCA1, ABCG1 and 
SRB1 expression [35]. Furthermore, Curcumin an active compound in turmeric has been 
shown to increase ABCA1 gene expression while down regulating expression of SRA1 in 
J774A.1 macrophages [32]. In another study that used the same cell line, treatment with α-
lipoic acid increased ABCA1 expression via induction of LXR-α [30].  In addition to these, 
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Vitamin E is also a potent bioactive compound which has been widely researched for its 
anti-oxidant, anti-cancer and anti-inflammatory properties [36].  
1.4 Tocotrienols: A form of Vitamin E 
Vitamin E was first discovered in 1922 and was extracted from alfalfa leaves to prevent 
placental hemorrhage in a rat model [37]. Two major isoforms of Vitamin E have been 
identified, namely tocopherols and tocotrienols. Each form is naturally available as 
chemically distinct isomers namely alpha (α), beta (β), gamma (Ƴ) and delta (δ) making 
total number of vitamin E isomers into 8 (Figure 1.5) [38]. The structure of tocopherols 
compromises a chromanol ring and saturated hydrocarbon chain while tocotrienols have a 
similar chromanol ring but an unsaturated hydrocarbon chain with three double bonds [39]. 
Tocotrienols mainly found in palm oil, rice bran oil, barley germ and annatto. Palm oil has 
considerably higher amount of tocotrienols (940 mg/kg) and rice bran oil contains 465 
mg/kg of tocotrienols [37]. In addition, tocotrienols are also found in olive oil, hazelnuts, 
maize, rye, flax seed oil, sunflower oil and grape fruit seed oil.       
 
                   
   
                                          
 
                                    Figure 1.5: Isomers of Vitamin E  (Source: Lu et al [38]) 
Being hydrophobic by nature, tocopherols and tocotrienols require an aid to penetrate the 
cell membrane. It has been found out that transport of tocotrienols and tocopherols into 
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cells occur via a special protein called tocopherol transfer protein (TTP) [36]. Although 
TTP has a higher affinity for tocopherols compared to tocotrienols, the unsaturation side 
chain of tocotrienols is known to facilitate better penetration of tocotrienols into fatty layers 
such as brain and liver [37, 40]. Also, tocotrienols are believed to incorporate and transfer 
between cell membranes more efficiently than tocopherols [41]. In addition, tocotrienols 
are  believed to have a better distribution in the cell membranes and are known to 
accumulate in endothelial cells, 10 times higher than tocopherols which may account for 
its higher anti-oxidant, anti-cancer, hypocholesterolemic properties compared to 
tocopherols [42, 43]. 
Upon consumption, tocotrienols are cleaved by an esterase located in the small intestine 
and absorbed together with fat with the help of bile acids [37]. Absorbed tocotrienols are 
then packaged into chylomicrons and enter the lymphatic system. In the liver and 
peripheral tissues, they are digested by lipoprotein lipase that release constituents of 
lipoproteins, which then enter the tissues via receptor mediated endocytosis. In the body,  
highest amounts of tocotrienols are found in adipose tissue and adrenal gland [37].  
1.4.1 Properties of tocotrienols. 
Attention towards beneficial effects of tocotrienols arose in 1980’s and 1990’s when their 
hypocholesterolemic and anti-cancer properties were first discovered [37]. To date, a large 
number of research studies have been conducted to explore the anti-oxidative, anti-
inflammatory, hypocholesterolemic and anti-cancer properties of tocotrienols and to 
understand how these properties may provide protective effects on chronic diseases [36]. 
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Anti-oxidative properties:                                               
The oxidation of biological molecules such as lipids, proteins and DNA by ROS, is a 
leading cause of numerous pathological events, including, but not limited to CKD 
cancer and aging processes. The anti-oxidant function of tocotrienols is known to occur 
through its strong free radical scavenging activity, which breaks the free radical chain 
reaction. More interestingly, tocotrienol radical formed in this process is resonance 
stabilized due to the conjugated system of the chromanol ring in tocotrienols. These 
tocotrienol radicals are converted back to tocotrienols by the vitamin C and glutathione 
reductase system (Figure 1.6) [44]. 
 
                              Figure 1.6: Anti-oxidative properties of tocotrienols 
(Source: El-Beltagi et al [44]) 
Apart from scavenging free radicals, tocotrienols are known to exert its anti-oxidative 
functions through modulating enzymes in anti-oxidant system such as glutathione S-
transferase (GST). In cultured rat hepatocytes treatment with tocotrienols and tocopherols 
together significantly decreased GST level in 3 days [37, 42]. In the same cell culture 
model, tocotrienol alone significantly decreased GST level in 1-3 days, with more 
prominent effect seen at concentration above 50 µM, compared to control and tocopherol 
[42].  
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In a Streptozotocin (STZ) induced diabetic nephropathy rat model treatment with 
tocotrienols (100 mg/kg) for 8 weeks, significantly reduced TABARs, a lipid peroxidation 
product, compared to control group [43]. In addition, treatment with a combination of 
insulin and tocotrienol significantly reduce the increase in TBARS compares to rats treated 
with insulin and tocotrienol alone [37]. 
Anti-diabetic properties: 
Diabetes is the leading cause of CKD and 30-40 % of patents with type I diabetes and 15% 
of patients with type II diabetes develop ESRD. Tocotrienols have shown anti diabetic 
properties in different models. In Streptozotocin (STZ) induced diabetic rat model, 
treatment with tocotrienols (100mg/kg) for 8 weeks significantly decreased, superoxide 
dismutase and catalase enzyme activity compared to the control group. The effects seen in 
this model with tocotrienols are more prominent compared to effects seen with α-
tocopherol [43]. Treating STZ induced diabetic rat model with α-Tocotrienol (0.1 g/kg) 
significantly prevented increase in advanced glycation end products (AGE), MDA and 
blood glucose level [45]. Furthermore, intragastric supplementation of palm of TRF 
(200mg/kg) significantly reduced the blood glucose level and glycated hemoglobin level 
in STZ-induced diabetic rats [46]. 
Anti-inflammatory properties: 
CKD patients experience higher level of inflammation compared to a healthy population. 
Anti-inflammatory properties of tocotrienols have been tested on both cell culture and 
animal models, mostly using Lipopolysaccharide (LPS), a compound that is widely used 
to induce inflammation in cell culture experiments. In a study by Yam et al, induction with 
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LPS increased the expression of various inflammatory markers such as TRF-α, IL-6, COX-
1, COX-2 in RAW.247 macrophages and incubation with 10 µg/ml of delta -tocotrienols 
for 24 hours significantly reduced the expression of these inflammatory makers [47]. In 
addition, treatment with LPS induced THP-1 macrophages with tocotrienols (0.5, 1.0 and 
5.0 µg/ml) significantly and dose dependently reduced proinflammatory cytokines such as 
TRF-α, IL-4 and IL-8 and expression of NFκB [48]. In rats with STZ induced diabetic 
nephropathy, tocotrienols significantly and dose dependently decreased expression of 
NFκB, TNF-α and TGF-β1 which are increased due to STZ. It was found out that anti-
inflammatory effect seen with tocotrienol is more prominent than tocopherol alone [43]. 
Hypolipidemic properties: 
Tocotrienols also have shown hypolipidemic properties in both animals and humans. 
Ability of Tocotrienols to reduce plasma cholesterol level is reported to mediated by 
reducing HMG-CoA reductase activity, the rate limiting enzyme in cholesterol synthesis 
[37].  In another clinical study, supplementation of tocotrienols (75 mg/day) for 2 months, 
significantly reduced fasting blood lipid levels (31). In this study, total cholesterol (TC) 
and LDL-cholesterol (LDL-C) were dropped by 13% and 9-15% respectively, whereas 
high density lipoprotein-cholesterol (HDL-C) was increased by 4-7% at the end of the 
treatment [37]. In STZ induced diabetic rat model, treatment with TRF (200 mg/Kg body 
weight) for 8 weeks, significantly decreased plasma total cholesterol level, TG level, LDL 
level and significantly increased plasma HDL level compared to untreated group [46]. In a 
pre-clinical study conducted by our lab, hemodialysis patients supplemented with 
tocotrienols (two soft gels containing 90 mg of tocotrienols and 20 mg of α-tocopherols 
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per day) for 16 weeks, had significant reduction in plasma triglycerides levels and 
significant increase in plasma HDL levels, compared to placebo group [49]. 
Anti-cancer properties: 
Tocotrienols have shown beneficial effects on different types of cancers such as lung, 
prostate, breast, colon cancer cell models [36]. Among these, Non-small cell lung cancer 
(NSCLC) is one of the leading cause of cancer deaths worldwide  accounting for 20% of 
all cancer deaths and 80% for all lung cancer events [50]. Effects of tocotrienols on NSCLC 
have been extensively studied by Gupta lab in our department [50-52]. Based on their 
findings, δ-tocotrienols have shown to inhibit cancer cell proliferation, migration, invasion 
and induce apoptosis in NSCL cancer cell lines such as A549 and H1299 [50-52]. 
According to the Ph.D dissertation by L. Rajasinghe [53] similar effects are seen with TRF 
derived from palm oil. In these studies, they found out that tocotrienols exert its anti-cancer 
effects via inhibiting Notch-1 signaling pathway which involves cell proliferation, 
migration and invasion of NSCL cancer cells [50-53]. 
1.4.2 Effects of tocotrienols on RCT  
Increase in reverse cholesterol transport is considered to reduce the risk for atherosclerosis. 
Based on recent studies, tocotrienols have affect several important enzymes and genes 
involve in RCT [49, 54].  In ApoE deficient mice, tocotrienols have shown to reduce 
atherosclerosis via inducing PPAR-γ and its down-stream genes such as LXR-α, suggesting 
tocotrienols can act as potential PPAR-γ agonists in reducing atherosclerosis [54]. Since 
PPAR-γ is a key regulator in cholesterol efflux, increase in PPAR-γ due to tocotrienols, 
may increase cholesterol efflux, which can reduce foam cell formation. 
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1.4.3 Clinical intervention study: Effects of TRF in hemodialysis population  
Patients with ESRD have an increased risk for atherosclerosis due to elevated oxidative 
stress, inflammation and altered lipid metabolism [8]. In a randomized, double blinded, 
placebo controlled, clinical intervention study conducted by our lab, we found out that TRF 
supplementation significantly improved lipid profile in hemodialysis population. Eighty-
one hemodialysis patients participated in this study and patients were given vitamin E 
tocotrienol-rich fraction (TRF) (180 mg tocotrienols, 40 mg tocopherols) or placebo (0.48 
mg tocotrienols, 0.88 mg tocopherols) for 16 weeks [49].  Based on our findings, 
supplementing ESRD patients with TRF capsules for 16 weeks, showed increase in 
normalized plasma HDL (of baseline) at both 12 and 16 weeks compared to placebo. 
Similarly, TRF supplementation decreased normalized plasma TG (of baseline) at both 12 
and 16 weeks compared to placebo. In addition, at 12 and 16 weeks, TRF supplementation 
showed increase in plasma Apo-A1 levels and decreased plasma CETP activity compared 
to placebo and baseline [49]. Decreased CETP activity and increased cholesterol acceptors 
such as HDL and Apo-A1 suggest that TRF may have beneficial effects in promoting 
reverse cholesterol transport in these patients. 
Using the same capsules used in our pre-clinical study, Rajasinghe et al explored potential 
anti-cancer properties of TRF on NSCLC invitro. Based on their unpublished data, TRF 
dose dependently inhibited NSCLC proliferation, migration, tumor cell invasion and 
induce apoptosis through down regulating Notch-1 and NFκB pathways*. Findings of  
                                                          
* Rajasinghe, L. and S. Gupta, Tocotrienols suppress non-small lung cancer cells via downregulation of the    
  Notch-1 signaling pathway (644.1). The FASEB Journal, 2014. 28(1 Supplement): p. 644.1  
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These invitro studies further validate the multiple health benefits associated with TRF such 
as anti-cancer effects.  
Objective: 
In the pilot study conducted by our lab, we found out that TRF derived from palm oil 
increased both plasma HDL and Apo-A1 and reduced CETP in ESRD patients. The 
increase in HDL and Apo-A1 and decrease in CETP activity observed in patients 
supplemented with TRF may promote RCT, which can increase removal of excess 
cholesterol from the body. Apart from affecting plasma HDL, Apo-A1 and CETP all of 
which participate in latter stages of RCT, TRF may also affect cholesterol efflux, an early 
step in RCT. Furthermore, based on studies by Rajasinghe et al *, content of these TRF 
capsules have shown to exhibit anti-cancer effects on NSCLC, further supporting multiple 
health benefits associated with TRF which was used on our pilot study.  To further explain 
these effects with TRF in ESRD patients, a multi-centered intervention study is being 
conducted by our lab (clinicaltrials.gov registration number: NCT02358967) with various 
dialysis units, with much larger number of ESRD population. Therefore, before starting 
our multi-centered clinical intervention study, we wanted to evaluate the potential effects 
of TRF capsules that will be given for ESRD patients on cholesterol efflux, and evaluate 
its anti-cancer effects on NSCLC. To achieve the above, this study was designed to use the 
contents of new TRF and placebo capsules which are to be used in the clinical trial to 
evaluate their,  
•  anti-cancer properties in NSCLC cell line (A549) and 
•  ability to improve cholesterol efflux in J774A.1 macrophages. 
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It was hypothesized that contents of TRF capsules can promote cholesterol efflux in 
J774A.1 macrophages. 
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CHAPTER 2: Material and Methods 
2.1 Cell culture of A549 and treatments. 
A549 cells (ATCC) were kindly provided by Prof. Smiti Gupta. Cells were grown in 
complete media at 37⁰C in 5% CO2 in a humidified atmosphere (standard cell culture 
conditions for A549 cells). Complete media (RPMI 1640 with 10% FBS and 1% 
Penicillin/Streptomycin) for A549 cells were prepared by adding 50 ml of FBS (Fisher 
Scientific, Waltham, MA) and 5 ml of 100 U/ml Penicillin and 100 mg/ml Streptomycin 
(Fisher Scientific, Waltham, MA) into 500 ml RPMI 1640 media (Fisher Scientific, 
Waltham, MA). Media was changed every 2 days and cell passaging was done using 
Trypsin/EDTA (Fisher Scientific, Waltham, MA) when cells became 85-90% confluent. 
To test the anti-cancer properties, TRF and placebo capsules (Caroteno, Malaysia) 
manufactured at three different time points, were used. The first batch (TRF 1) had been 
manufactured in 2012. Batch 2 (TRF 2 and placebo 2) and batch 3 (TRF 3 and placebo 3) 
were manufactured in 2016 and 2017 respectively. To prepare stock solutions of TRF and 
placebo, 100 mg of capsule content was taken from each capsule and dissolved in 1 ml of 
DMSO (Sigma Aldrich, St. Louis, MO) in cryo-vials covered with a foil. Stock solutions 
were stored in -20°C and used within one month.   
2.2 Cell viability assays (MTS assay) on A549 cells. 
Following procedure was used to test the anti-cancer properties of TRF and placebo for all 
TRF and placebo batches. Cells were seeded in 96-cell culture plates at a density of 
5x103/100µl/well and incubated overnight at standard cell culture conditions for A549 
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cells. Treatments (20,40,60,80 µg/ml) were prepared by diluting TRF and placebo stock 
solutions with media. Complete media was used as the control. After 24 hours of seeding, 
old media was removed, 100 µl of treatment media was added and incubated for another 
72 hours at standard cell culture conditions for A549 cells. At the end of 72 hours, Promega 
Cell titer 96 Aqueous one solution reagent/MTS reagent (Fisher Scientific, Waltham, MA) 
was diluted with PBS (Fisher Scientific, Waltham, MA) in 1: 1 ratio and 20 µl of diluted 
MTS reagent was added to each well. Cells were then incubated for another 3 hours at 
standard cell culture conditions. After 3 hours, plates were shaken for 30 seconds and 
absorbance was read at 492 nm using SkanIt spectrophotometer (Thermofisher scientific, 
Waltham, MA). Cell viability was calculated by subtracting post-absorbance from pre-
absorbance and relative cell viability was calculated as follows. 
           Relative cell viability = Mean cell viability of treatment 
                                                 Mean cell viability of control  
2.3 Western-blot analysis for Notch-1 protein. 
To analyze protein expression of Notch-1 gene, A549 cells were seeded at a density of 
1x106/ml/petri dish (100 mm) and incubated for 24 hours. Cells were then treated with 40, 
80, 120 µg/ml concentrations of TRF for 72 hours. Complete media was used as the control. 
After 72 hours cells were lysed with a mixture of 1x lysis buffer and 1x protease inhibitor 
(Cell Signaling Technology, Danvers, MA). Next the protein concentrations were 
determined using BSA assay (Bio-Rad Laboratories, CA) and 40 µg of total protein was 
mixed with 4x Lemma buffer (Bio-Rad Laboratories, CA) and loaded into 10% SDS-
PAGE gel. After electrophoresis, the gel was transferred into PVDF membrane using 
X 100 
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Trans-Blot® TurboTM Transfer System (Holliston, MA). Then the membrane was 
incubated with 5% Casein for 2 hours at room temperature and incubated with Notch-1 
primary antibody (Cell Signaling Technology, Danvers, MA) diluted at 1:4000, for an 
overnight at 4°C. Then the membrane was washed three times with PBS-T, and incubated 
with the secondary antibody (Cell Signaling Technology, Danvers, MA), diluted 1:5000, 
in 2% Casein for 2 hours. Subsequently, the membrane was immersed in the substrate 
solution (Bio-Rad Laboratories, CA) for 5 minutes and signal intensity was observed using 
a chemiluminescent imager with chemiDoc XRS (Bio-Rad Laboratories, CA). 
2.4 Cell Culture of J774A.1 and Treatments 
J774A.1 macrophages (ATCC® TIB-67™, Manassas, VA) were grown in complete media at 
37⁰C in 10% CO2 in a humidified atmosphere (standard cell culture conditions for J774A.1 
cells). Complete media was prepared by adding 50 ml of FBS (Fisher Scientific, Waltham, 
MA) and 5 ml of 100 U/ml Penicillin and 100 mg/ml Streptomycin (Fisher Scientific, 
Waltham, MA) to 500 ml of DMEM (Life Technologies (Carlsbad, CA).  Cells were first 
seeded in a T-25 flask and culture media was changed every day until the cells became 85-
90% confluent. Once cells reached 85-90% confluency, cells were split using a sterile 
scraper and seeded in a T-75 flask. Cells were maintained by changing media every day 
and splitting into 1:3 ratio. Stock solutions from all TRF and placebo batches were prepared 
as described in section 2.1. 
2.5 Cell viability assay (MTS assay) with TRF and Placebo for J774A.1 cells 
To perform the MTS assay, cells were seeded in 96 cell culture plates at a density of 
1x104/100µl/well and incubated overnight at standard cell culture conditions. From TRF 
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and placebo stock solutions, 20,40, 60, and 80 µg/ml of working treatments were prepared. 
After 24 hours of seeding, media was removed, 100 µl of treatment media was added and 
incubated for another 48 hours at standard cell culture conditions. Complete media was 
used as the control. At the end of 48 hours incubation, MTS assay was performed and 
relative cell viability was calculated as described in section 2.2.  
2.6 RNA extraction  
For RNA extraction, J774A.1 cells were seeded in sterile cell culture petri dishes (100 mm) 
at a cell density of 1x106/ml/petridish for 24 hours. After 24 hours, cells were treated with 
10 ml of TRF (8 µg/ml, 16 µg/ml) for 24 and 48 hours and with placebo (8 µg/ml, 16 
µg/ml) for 48 hours.  Complete media was used as the control. After 24 and 48 hours of 
incubation, RNA was extracted using Qiagen RNeasy mini kit (Qiagen, Hiden, Germany) 
according to manufacturer’s instructions. 
Briefly, treatment media was removed and cells were washed with ice-cold PBS. Then 700 
µl of QIAzol reagent was added to cell layer and scraped using a sterile cell scraper. Cell 
homogenate was then incubated at room temperature for 5 minutes and vortexed vigorously 
for 15 seconds after adding chloroform.  The mixture was again incubated at room 
temperature and centrifuged to obtain the upper aqueous layer containing nucleic acid. To 
this 100 % ethanol was added, mixed thoroughly and transferred to RNeasy Mini column 
in a 2 ml collection tube. After centrifugation, the flow through was discarded and the same 
step was repeated with remaining sample. Next, buffer RWT was added and centrifuged 
for another 15 seconds. Then, buffer RPE was added to the column and centrifuged for 15 
seconds. Same step was repeated for another 2 minutes. To further dry the membrane, 
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empty column was centrifuged for 1 minute. RNeasy mini column was then placed in an 
empty 1.5 ml collection tube and 50 µl of RNase-free water was directly added onto the 
membrane. The column was centrifuged for 1 min at 8000xg to elute bound RNA. Isolated 
RNA samples were stored at -80°C. 
2.7 RNA quantification and cDNA synthesis 
RNA quantification was performed using Nanodrop. cDNA was synthesized using High 
Capacity RNA-to-cDNA (Fisher Scientific, Waltham, MA) according to manufacturer’s 
instructions. Briefly, 10 µl of 2x RT buffer, 1 µl of 20x RT enzyme, 2000 ng of extracted 
RNA and nuclease free water to make the total volume up to 20 µl were mixed in a sterile 
PCR tube. Reverse transcription reaction was performed by incubating the reaction for 
37°C for 60 minutes, stopping the reaction by heating to 95°C for 5 minutes and holding 
at 4°C. cDNA synthesis was performed in Eppendorf Master cycler realplex 4 (Eppendorf, 
Hauppauge, NY). cDNA samples were stored in -80°C.  
2.8. Real-time PCR 
Real-time PCR primers for genes to be tested were taken from peer-reviewed papers and 
are summarized in the Table 2.1 [55-58]. All these primers were purchased from Life 
Technologies, Carlsbad, CA. Real-time PCR was performed using Power-up SYBR green 
master mix (Fisher Scientific, Waltham, MA) in Eppendorf Master cycler realplex 4 
(Eppendorf, Hauppauge, NY). GAPDH was used as the house-keeping gene. Cycle 
parameters used were as follows: UDG activation at 50°C for 2 minutes, extension by dual 
lock DNA polymerase at 95°C for 2 minutes, denaturation at 95°C for 15 seconds, 
annealing at 55-60 °C for 15 seconds and extension at 72°C for 1 minute. Gene expression 
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was expressed as fold change (2-ΔΔCT). Two-fold increase (≥2) or 2-fold decrease (≤ 0.5) 
compared to the control in each treatment group was considered to be significant. 
Table 2.1 Real-time PCR primers 
Gene Forward Primer Reverse Primer 
GAPDH 
[57] 
5-AACTTTGGCATTGTGGAAGGG- 3 5-GACACATTGGGGGTAGGAACAC-3 
PPAR-γ 
[56] 
5-GGAAGACCACTCGCATTCCTT-3 5-GTAATCAGCAACCATTGGGTCA-3 
CD-36 
[55] 
5-AGGTCTATCTACGCTGTGTTC-3 5-TGGTTGTCTGGATTCTGGAG-3 
SRA1 
[55] 
5-AGAGGGCTTACTGGACAAACTG-3 5-GGCTTTCCTGGTGCTCCTG-3 
SRB1 
[57] 
5-ATGGGCCAGCGTGCTTTTATGA-3 5-AACCACAGCAACGGCAGAACTA-3 
LXR-α 
[59] 
5-CAATGCCTGATGTTTCTCC-3 5-TGACTCCAACCCTATCCCTA-3 
ABCG1 
[58] 
5-TTCATCGTCCTGGGCATCTT-3 5-CGGATTTTGTATCTGAGGACGAA-3 
ABCA1 
[57] 
5-AGCTGCCCCATCATGTAAAG-3 5-GGGAGAAGAGCGTGCTAATG-3 
 
2.9 Statistical Analysis 
Statistical analysis between treatment and control groups were analyzed using one-way 
ANOVA (ezANOVA, USA). Statistical significance was set at p<0.05.  
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CHAPTER 3: Results 
3.1 TRF dose dependently inhibited A549 cell proliferation. 
TRF is known to inhibit cancer cell proliferation. To verify that contents of TRF capsules 
are active, the anti-cancer properties of different TRF batches (TRF 1, 2 and 3) were tested 
using NSCLC cell line (A549). A549 cells were seeded at a density of 5x103 
cells/100µl/well and treated with 40, 80, 120 µg/ml of TRF or placebo for 72 hours. 
Complete media was used as the control. Based on the results of MTS assays, all TRF 
batches significantly inhibited growth of A549 cells at the concentration of 80 µg/ml and 
no significant inhibition was observed with placebo treatments (Figure 3.1 (A)).  
3.1.1 TRF dose dependently inhibited Notch-1 protein expression 
Expression of Notch-1 is known to modulate cancer cell proliferation in many types of 
cancers such as colon, pancreatic, lung, breast and skin. To test the effects of TRF on notch-
1 expression in A549 cell lines a western-blot analysis was performed.  Cells were seeded 
at a density of 1x106 cells/ml and treated with 40,80,120 µg/ml of TRF for 72 hours. Based 
on western blot data, 40, 80, 120 µg/ml of TRF dose dependently decreased Notch-1 
protein expression (Figure 3.1(B)). 
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Figure 3.1 Effects of TRF and placebo batches on A549 cell proliferation and effect 
of TRF on Notch-1 expression 
 
(A) MTS assay was used to determine anti-cancer effects of different batches of TRF and 
placebo on A549 cells. Cells were seeded at a density of 5000 cells/100µl/well and 
incubated with 40, 80 and 120 µg/ml of TRF and placebo separately for 72 hours. Vertical 
axis shows the mean relative cell viability ± SD.  Statistical significance determined using 
One way ANOVA with TukeyHSD multiple comparison test (ezANOVA, USA). 
Statistical significance was set at p < 0.05. Statistical significance for TRF 1 compared to 
control is denoted as “*”. Statistical significance for TRF 2 compared to control is denoted 
as “#”. Statistical significance for TRF 3 compared to control is denoted as “×”. 
(B) Expression of TRF on Notch-1 protein expression was analyzed using western-blot 
analysis, after treating cells (1x106/ml) with 40, 80, 120 µg/ml of TRF for 72 hours. 
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3.2 TRF-2 concentrations up to 20 µg/ml did not cause cytotoxicity in J774A.1 cells. 
 
To determine the non-cytotoxic concentrations of TRF for J774A.1 cells, MTS assay was 
performed.  Cells were seeded with 1x104 cells/100 µl/well and treated with 20, 40, 60, 80, 
100, 120 µg/ml concentrations for 48 hours. Based on the results of MTS assay more than 
90% relative cell viability was observed with 20 µg/ml of TRF (Figure 3.2). 
Concentrations of 40, 60,80, 100 and 120 µg/ml of TRF, significantly reduced cell growth 
with relative cell viabilities of 72%, 31%, 3%, 2.3% and 2.1% respectively, compared to 
the control. No significant effect was observed with treatment with placebo on cell growth 
at given concentrations for 48 hours. Based on MTS assay data, concentrations less than 
20 µg/ml were selected for gene expression experiments. 
3.3 TRF-2 increased PPAR-γ gene expression. 
Increased expression of PPAR-γ is known to increase cholesterol efflux. To test the effect 
of TRF and placebo on PPAR-γ gene expression, cells were seeded at a density of 1x106 
cells/ml and treated with 8, 16 µg/ml of TRF-2 for 24 hour and 48 hours and with placebo 
(8, 16 µg/ml) for 48 hours. Complete media was used as the control. PCR data revealed 
that treatment with TRF-2 for 24 hours with 8 and 16 µg/ml caused a significant dose 
dependent increase in PPAR-γ compared to the control (Figure 3.3 (A)).  In 48 hour 
treatments, no significant change was observed at 8 µg/ml, but a significant 2.93 increase 
in fold change was observed for 16 µg/ml compared control (Figure 3.3 (B)). Treatment 
with placebo for 48 hours did not cause any dose dependent effect compared to control 
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(Figure 3.3 (C)). Among tested conditions, highest increase of PPAR-γ (2.93x increase 
compared to control) was observed with 16 µg/ml for 48 hours.  
 
Figure 3.2 Effects of TRF-2 and placebo-2 on cell viability of J774A.1 macrophages 
MTS assay was used to determine cytotoxic effects of TRF-2 and placebo-2 on J774A.1 
macrophages. Cells were seeded at a density of 1x104/100µl/well and incubated with 20,40, 
60, 80, 100 and 120 µg/ml of TRF-2 and placebo-2 separately.  Complete media was used 
as the control. Vertical axis shows the mean relative cell viability ± SD.  Statistical 
significance determined using One way ANOVA with TukeyHSD multiple comparison 
test (ezANOVA, USA). Statistical significance compared to control is denoted as “*” (p < 
0.05). 
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Figure 3.3 Effects of TRF-2 and placebo-2 on PPAR-γ 
Effects of TRF-2 and placebo-2 on PPAR-γ was tested using real-time PCR. J774A1 cells 
were seeded at a cell density of 1x106/ml for 24 hours. Cells were then treated with 8 µg/ml 
16 µg/ml of TRF-2 for 24 hours and 48 hours and with placebo-2 (8 µg/ml 16 µg/ml) for 
48 hours.  (A) Effects of TRF-2 at 24 hours (B) Effect of TRF-2 at 48 hours (C) Effects of 
placebo at 48 hours. The vertical axis indicates the mean relative expression (calculated 
using 2-ΔΔCT method) ± SD. Two-fold increase or decrease compared to control was 
considered significant. Significant difference in TRF 2- 24 hours compared to control is 
denoted as “#”. Significant difference in TRF 2- 48 hours compared to control is denoted 
as “*”. GAPDH was used as the house keeping gene. 
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3.4 TRF-2 decreases SRA1 gene expression. 
SRA1 facilitates uptake of oxidized LDL into the macrophages. To test the effect of TRF-
2 on expression SRA1 expression, cells were seeded at a density of 1x106 cells/ml and 
treated with 8, 16 µg/ml of TRF-2 for 24 hour and 48 hours and with placebo-2 (8, 16 
µg/ml) for 48 hours.  Based on real-time PCR data, treatment with 8 and 16 µg/ml of TRF-
2 at 24 hours did not show any significant changes in the expression of SRA1 compared to 
the control.  (Figure 3.4 (A)). With 48-hour treatment, no significant change was observed 
for 8 µg/ml of TRF-2 compared to control (Figure 3.4 (B)). However, a significant 
reduction was observed with 48-hour treatment at 16 µg/ml compared to the control. As 
shown in Figure 3.4 (C), no dose dependent and/or time dependent effect was observed 
with placebo. Among tested conditions, lowest expression of SRA1 (4.9x decrease 
compared to control) was observed with 16 µg/ml for 48 hours. 
3.5 TRF-2 increased CD-36 gene expression. 
CD-36 is also involved in the uptake of oxidized LDL into macrophages. To test the effect 
of TRF-2 gene expression CD-36, cells were seeded at a density of 1x106 cells/ml and 
treated with 8, 16 µg/ml of TRF-2 for 24 hour and 48 hours and with placebo (8, 16 µg/ml) 
for 48 hours. Treatment with TRF-2 for 24 hours with 8 and 16 µg/ml did not cause any 
significant changes in the expression of CD-36 compared to control (Figure 3.5 (A)).  
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Figure 3.4 Effects of TRF-2 and placebo-2 on SRA1 
Effects of TRF-2 and placebo-2 on PPAR-γ was tested using real-time PCR. J774A1 cells 
were seeded at a cell density of 1x106/ml for 24 hours. Cells were then treated with 8 µg/ml 
16 µg/ml of TRF-2 for 24 hours and 48 hours and with placebo-2 (8 µg/ml 16 µg/ml) for 
48 hours.  (A) Effects of TRF-2 at 24 hours (B) Effect of TRF-2 at 48 hours (C) Effects of 
placebo at 48 hours. The vertical axis indicates the mean relative expression (calculated 
using 2-ΔΔCT method) ± SD. Two-fold increase or decrease compared to control was 
considered significant. Significant difference in TRF 2- 24 hours compared to control is 
denoted as “#”. Significant difference in TRF 2- 48 hours compared to control is denoted 
as “*”. GAPDH was used as the house keeping gene. 
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Figure 3.5 Effects of TRF-2 and placebo-2 on CD-36 
Effects of TRF-2 and placebo-2 on PPAR-γ was tested using real-time PCR. J774A1 cells 
were seeded at a cell density of 1x106/ml for 24 hours. Cells were then treated with 8 µg/ml 
16 µg/ml of TRF-2 for 24 hours and 48 hours and with placebo-2 (8 µg/ml 16 µg/ml) for 
48 hours.  (A) Effects of TRF-2 at 24 hours (B) Effect of TRF-2 at 48 hours (C) Effects of 
placebo at 48 hours. The vertical axis indicates the mean relative expression (calculated 
using 2-ΔΔCT method) ± SD. Two-fold increase or decrease compared to control was 
considered significant. Significant difference in TRF 2- 24 hours compared to control is 
denoted as “#”. Significant difference in TRF 2- 48 hours compared to control is denoted 
as “*”. GAPDH was used as the house keeping gene. 
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No significant changes were observed with 48-hour treatment at 8 µg/ml but a significant 
increase in CD 36 was observed at 16 µg/ml compared to the control (Figure 3.5 (B)). No 
significant changes were observed with 8 and 16 µg/ml of placebo compared to control for 
48 hours (Figure 3.5 (C)). Based on these data, highest significant increase of CD-36 
expression (2.2x compared to control) was observed with 16 µg/ml TRF-2 for 48 hours, 
under tested conditions. 
3.6 TRF-2 increased SRB1 gene expression. 
SRB1 facilitates cholesterol efflux by releasing free cholesterol into HDL-2 particles.  
Therefore, effect of TRF-2 and placebo-2 on SRB1 gene expression was tested using real-
time PCR. Cells were seeded at a density of 1x106 cells/ml and treated with 8, 16 µg/ml of 
TRF-2 for 24 hour and 48 hours. Cells were also treated with placebo-2 (8, 16 µg/ml) which 
contained wheat germ oil as the major component, for 48 hours.  Based on real-time PCR 
data, treatment with 8 and 16 µg/ml of TRF-2 for 24 hours did not cause any significant 
changes compared to control (Figure 3.6 (A)). In contrast, 48-hour treatment caused a 
significant dose dependent increase in SRB1 expression compared to control (Figure 3.6 
(B)). Treatment with 8 and 16 µg/ml of placebo-2 did not cause any significant changes in 
SRB1 expression after 48 hours treatment (Figure 3.6 (C)). Based on these results, highest 
significant increase SRB1 expression occurred with TRF-2 of 16 µg/ml for 48 hours (4x 
increase compared to control) under tested conditions. 
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 Figure 3.6 Effects of TRF-2 and placebo-2 on SRB1 
Effects of TRF-2 and placebo-2 on PPAR-γ was tested using real-time PCR. J774A1 cells 
were seeded at a cell density of 1x106/ml for 24 hours. Cells were then treated with 8 µg/ml 
16 µg/ml of TRF-2 for 24 hours and 48 hours and with placebo-2 (8 µg/ml 16 µg/ml) for 
48 hours.  (A) Effects of TRF-2 at 24 hours (B) Effect of TRF-2 at 48 hours (C) Effects of 
placebo at 48 hours. The vertical axis indicates the mean relative expression (calculated 
using 2-ΔΔCT method) ± SD. Two-fold increase or decrease compared to control was 
considered significant. Significant difference in TRF 2- 24 hours compared to control is 
denoted as “#”. Significant difference in TRF 2- 48 hours compared to control is denoted 
as “*”. GAPDH was used as the house keeping gene. 
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3.7 TRF-2 did not affect LXR-α gene expression. 
 
LXR-α is a downstream gene of PPAR-γ and is an upstream gene to cholesterol efflux 
genes such as ABCA1 and ABCG1. To test the effect of TRF on LXR-α and ABCG1 gene 
expressions, cells were seeded at a density of 1x106 cells/ml and treated with 8, 16 µg/ml 
of TRF-2 for 24 hour and 48 hours and with placebo (8, 16 µg/ml) for 48 hours. Based on 
PCR data, no significant effects were observed with 8 and 16 µg/ml of TRF-2 at 24 hours 
and 48 hours (Figure 3.7 (A and B)). Also, no significant effects were observed with 
treatment of 8 and 16 µg/ml of placebo-2 for 48 hours (Figure 3.7 (C)).  
3.8 TRF-2 did not affect ABCG1 gene expression. 
ABCG1 is a cholesterol efflux gene downstream to LXR-α. No significant changes were 
observed with ABCG1 expression under tested conditions. (Figures 3.8 (A), (B) and (C)). 
3.9 TRF-2 decreased ABCA1 gene expression. 
ABCA1 aids efflux of free cholesterol into Apo-A1 particles. To test the effect of TRF-2 
and placebo-2 on LXR-α and ABCG1 gene expressions, cells were seeded at a density of 
1x106 cells/ml and treated with 8, 16 µg/ml of TRF-2 for 24 hour and 48 hours and with 
placebo-2 (8, 16 µg/ml) for 48 hours. Figure 3.9 (A and B) summarized effects of TRF-2 
on ABCA1 overtime. Treatment with 8 and 16 µg/ml for 24 hours significantly reduced 
ABCA1 expression compared to the control. A significant 2.8 reduction was observed for 
both 8 and 16 µg/ml with 48 hours treatment compared to control. Treatment with placebo-
2 did not cause any significant changes in ABCA1 gene expression (Figure 3.9 (C)). 
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Figure 3.7 Effects of TRF-2 and placebo-2 on LXR-α 
Effects of TRF-2 and placebo-2 on PPAR-γ was tested using real-time PCR. J774A1 cells 
were seeded at a cell density of 1x106/ml for 24 hours. Cells were then treated with 8 µg/ml 
16 µg/ml of TRF-2 for 24 hours and 48 hours and with placebo-2 (8 µg/ml 16 µg/ml) for 
48 hours.  (A) Effects of TRF-2 at 24 hours (B) Effect of TRF-2 at 48 hours (C) Effects of 
placebo at 48 hours. The vertical axis indicates the mean relative expression (calculated 
using 2-ΔΔCT method) ± SD. Two-fold increase or decrease compared to control was 
considered significant. Significant difference in TRF 2- 24 hours compared to control is 
denoted as “#”. Significant difference in TRF 2- 48 hours compared to control is denoted 
as “*”. GAPDH was used as the house keeping gene                            
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Figure 3.8 Effects of TRF-2 and placebo-2 on ABCG1 
Effects of TRF-2 and placebo-2 on PPAR-γ was tested using real-time PCR. J774A1 cells 
were seeded at a cell density of 1x106/ml for 24 hours. Cells were then treated with 8 µg/ml 
16 µg/ml of TRF-2 for 24 hours and 48 hours and with placebo-2 (8 µg/ml 16 µg/ml) for 
48 hours.  (A) Effects of TRF-2 at 24 hours (B) Effect of TRF-2 at 48 hours (C) Effects of 
placebo at 48 hours. The vertical axis indicates the mean relative expression (calculated 
using 2-ΔΔCT method) ± SD. Two-fold increase or decrease compared to control was 
considered significant. Significant difference in TRF 2- 24 hours compared to control is 
denoted as “#”. Significant difference in TRF 2- 48 hours compared to control is denoted 
as “*”. GAPDH was used as the house keeping gene. 
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Figure 3.9 Effects of TRF-2 and placebo-2 on ABCA1 
 
Effects of TRF-2 and placebo-2 on PPAR-γ was tested using real-time PCR. J774A1 cells 
were seeded at a cell density of 1x106/ml for 24 hours. Cells were then treated with 8 µg/ml 
16 µg/ml of TRF-2 for 24 hours and 48 hours and with placebo-2 (8 µg/ml 16 µg/ml) for 
48 hours.  (A) Effects of TRF-2 at 24 hours (B) Effect of TRF-2 at 48 hours (C) Effects of 
placebo at 48 hours. The vertical axis indicates the mean relative expression (calculated 
using 2-ΔΔCT method) ± SD. Two-fold increase or decrease compared to control was 
considered significant. Significant difference in TRF 2- 24 hours compared to control is 
denoted as “#”. Significant difference in TRF 2- 48 hours compared to control is denoted 
as “*”. GAPDH was used as the house keeping gene 
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Discussion: 
This study was conducted as a preliminary step of predicting potential beneficial effects of 
TRF capsules that will be given to ESRD patients in our multi-centered clinical 
intervention study. Based on our pilot study it was found out that TRF (78.7% tocotrienols, 
21.3% tocopherols) increased plasma HDL, Apo-A1 and decreased CETP activity in ESRD 
patients [49]. In addition, using same TRF capsules, Rajasinghe et al found out TRF inhibit 
NSCLC cancer cell (A549 cells) proliferation via inhibiting Notch-1 pathway, supporting 
that TRF used in our pilot study not only can improve lipid profiles but also have anti-
cancer properties.  
TRF-1 (78.7% tocotrienols, 21.3% tocopherols) was manufactured in 2012 and the new 
TRF (TRF-2 and TRF-3) were manufactured in late 2016 and early 2017 respectively. TRF 
2 and 3 have a similar composition (76.53% tocotrienols and 23.47% tocopherol) to the 
capsules that will be given to ESRD patients in our multi-centered study and were 
purchased as samples. Since Rajasinghe et al have shown anti-cancer effects of TRF on 
A549 cells, a NSCLC cell line*, we used the same cell line to identify whether the contents 
of new TRF capsules are active, using well-established anti-cancer properties of palm oil 
derived TRF on NSCLC cell line, A549. Based on the MTS assay, we found out that all 
three TRF batches significantly inhibited cancer cell proliferation at 80 µg/ml compared to 
control used for each batch. No significant cell growth inhibition was observed with 
placebo. Despite of having similar composition to TRF 1, TRF 2 and 3 showed more 
potency in cell growth inhibition at 80 µg/ml. Degradation of TRF in TRF-1 over time can 
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be a possible reason to the reduced cell growth seen with TRF-1 compared to TRF 2 and 3 
which were manufactured recently.   
Dose dependent decrease in cancer cell proliferation due to TRF -1 was further confirmed 
by a western-blot analysis of Notch-1 gene, which plays a critical role in cancer cell 
proliferation, differentiation and apoptosis in NSCLC.  Effects of TRF on Notch-1 
expression in NSCL has been extensively studied by Gupta lab in our department [50-52]. 
Ji et al found that treatment with pure δ-tocotrienol isomer, dose dependently inhibits 
proliferation of human NSCLC cell lines, A549 and H1299. Similarly, treatment with pure 
δ-tocotrienol isomer dose dependently reduced Notch-1  mRNA and protein expression 
[50, 52]. Studies by Rajasinghe et al* also reported similar effects on cancer cell 
proliferation and Notch-1 expression with TRF extracted from TRF capsules, further 
confirming beneficial effects of TRF on NSCL. Based on the results of MTS assays it was 
identified that contents in new TRF (TRF-2, TRF-3) capsules are active.  
Since cholesterol efflux can be promoted due to net effect of cholesterol influx and efflux 
gene expression, we then tested the effects of TRF-2 on expression of several genes in 
cholesterol efflux. Cholesterol efflux is the first step in reverse cholesterol transport, which 
is now considered as a novel predictor of CVD risk. To study the effects of TRF-2 on 
cholesterol efflux , J774A.1 cells, a well-established cell culture model which is widely 
used for cholesterol efflux studies  was used [15]. Based on a review by Annema et al, 30 
out 60 reported RCT studies are conducted with J774A.1 cell line, whereas  out of those 
                                                          
* Rajasinghe, L. and S. Gupta, Tocotrienols suppress non-small lung cancer cells via downregulation of the     
  Notch-1 signaling pathway (644.1). The FASEB Journal, 2014. 28(1 Supplement): p. 644.1 
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30, 10 reported effect of different commercially available drugs on RCT  [15]. 
Furthermore, it has also been used to test the effect of different naturally occurring 
bioactive compounds such as resveratrol, α-lipoic acid, curcumin on cholesterol efflux [29, 
30, 32].  
The non-cytotoxic treatment concentrations of TRF-2 for J774A.1 cell line was determined 
using MTS assay and based on MTS assay results, no cytotoxic effects were observed with 
concentrations from 0-20 µg/ml. Therefore, 8 and 16 µg/ml were selected as treatment 
concentrations. These treatment concentrations are in the range of treatment concentrations 
which have been used in several TRF studies [48, 60, 61]. In a study performed to test anti-
inflammatory properties of palm oil TRF on LPS- induced mouse peritoneal macrophages, 
TRF concentrations of 5, 10 and 30 µg/ml significantly reduced expression of 
inflammatory markers such as  nitric oxide (NO), prostaglandin E2 (PGE2), and 
proinflammatory cytokine (TNF-α, IFN-γ, IL-1β and IL-6) production [60].  
In another study which tested the potential effects of palm oil TRF on inhibition of vascular 
adhesion molecules in endothelial cells, treatment with lower TRF concentrations ranging 
from 10-50 ng/ml, did not affect cell viability and at the same time caused a significant 
dose dependent reduction of adhesion molecules expression [61]. However, concentrations 
above 20 µg/ml, caused a significant cell death in this study [61]. Furthermore, treatment 
with 0.5, 1.0, 5.0 µg/ml of palm oil TRF has shown dose dependent anti-inflammatory 
effects on THP-1 macrophages [48]. These studies further validate results obtained from 
MTS assay supporting that palm oil TRF can be effective at very low concentrations. 
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PPAR-γ is an important gene which is known to regulate anti-inflammatory and anti-
atherosclerosis properties. In this study, we found out that treatment with TRF-2 
significantly increased PPAR-γ expression. Similar agonistic effects of TRF on PPAR-γ  is 
reported in a study conducted by Li et using both macrophage and atherosclerotic mouse 
model [54]. More importantly TRF used in this study has a similar origin and composition 
of (76.53% tocotrienols and 23.47% tocopherol) to TRF-2 used in our study (74.68% 
tocotrienols and 23.5% tocopherol). In the cell culture model, treatment with 0.625, 2.5, 
10, 40 µg/ml of palm oil TRF dose dependently increased PPAR-γ   in RAW264.7 murine 
macrophages [54]. In fact, the increase of PPAR-γ observed at 10 µg/ml was similar to that 
of 1 µM rosiglitazone, a synthetic PPAR-γ agonist. In the mouse model, supplementation 
of  ApoE−/− mice  with an atherogenic diet together with 0.05% TRF, or 0.2% TRF for 16 
weeks significantly reduced the average lesion/aorta area  to 35.5% and 28.4% 
respectively[54].  These data further support our findings that TRF can act as a possible 
PPAR-γ agonist. 
PPAR-γ is known to modulate cholesterol influx by altering expression of its downstream 
cholesterol influx genes such as SRA1 and CD-36. Increased PPAR-γ expression is 
reported to increase CD36 while reducing SRA1, leading no net effect on cholesterol influx 
[20, 24, 25, 62]. In our study, we found out that treatment with TRF-2 significantly decrease 
SRA1 and significantly increase CD-36 expression. In a study performed by Moore et al, 
Troglitazone which is a synthetic PPAR-γ agonist and an antidiabetic thiazolidinediones 
(TZDs) drug, increased the expression of CD 36 and while decreasing SRA1, leading no 
net cholesterol influx in murine macrophages [24]. Rosiglitazone which is also a TZDs 
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drug and a synthetic PPAR-γ agonist, has also shown similar effects [25]. These data 
further support potential PPAR-γ   agonistic properties of TRF observed in this study. 
SBR1 is a cholesterol efflux genes, which is downstream to PPAR-γ. Upregulation of 
PPAR-γ   is known to increase SRB1 expression. Based on our results, TRF significantly 
increased SRB1 expression. Several studies report similar effects on SRB1 using PPAR-γ   
agonists. In a study conducted by Chinetti et al, C57BL/6J ApoE−/− mice supplemented 
with standard chow diet  (control group) or chow diet containing 0.2% (wt/wt) fenofibrate 
(synthetic PPAR-γ. agonist) or 1.4% (wt/wt) troglitazone ( synthetic PPAR-γ agonist)  for 
two weeks, an increased SRB1 protein expression was observed [62]. In another study, 
treatment of THP-1 macrophages for 24 hours with another synthetic PPAR-γ agonist, 
Telmisartan (1-20 µM) dose dependently increased SRB1 protein expression [63].  
In addition to these synthetic compounds, ferulic and caffeic acid which are naturally found 
in coffee has shown to increase SRB1 gene expression, dose dependently (0.25 – 1 µM) in 
THP-1 macrophages when treated for 6 hours[33]. These studies further support that TRF 
can increase SRB1 gene expression, via exerting PPAR-γ agonistic properties.  
Although the effect of SRB1 gene expression on SRB1-mediated cholesterol efflux is not 
measured in our study, results from recent studies show that increased SRB1 expression 
promotes SRB1 mediated cholesterol efflux. Ji et al reported that overexpression of SRB1 
in Chinese hamster ovary (CHO) cells, caused 4 fold increase in cholesterol efflux 
compared to control CHO cells [64]. Similarly, overexpression of SRB1 caused a 2.2 fold 
increased in cholesterol efflux to HDL, in RAW264.7 murine macrophages [65]. Since 
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TRF used in this project also increased SRB1 expression, it can be postulated that TRF 
used in this study may increase SRB1 mediated cholesterol efflux. 
PPAR-γ-LXR-α- ABCA1/ABCG1 pathway is one of the most studied cholesterol efflux 
pathway. Upregulation of PPAR-γ is known in increase gene expression of LXR-α- 
ABCA1 and ABCG1 genes. Although TRF increased PPAR-γ expression, we did not 
observe an increase in LXR-α and ABCG1 expression.  
In the study by Li et al, although treatment with TRF (0.625 – 40 µg/ml) significantly 
increased PPAR-γ expression, it did not cause a significant LXR-α expression, compared 
to 1 µM of synthetic LXR agonist T0901317 in RAW 264.7 macrophages [45]. However, 
in their in vivo study, Apo E−/− mice  fed with an atherogenic diet together with 0.05% 
TRF or 0.2% TRF for 16 weeks, caused a significant increase in LXR-α, ABCG1 and 
ABCA1 expression compared to synthetic PPAR-γ agonist, rosiglitazone [54]. In addition, 
in our study we observed that TRF-2 treatment significantly reduced ABCA1 gene 
expression. Therefore, to get more conclusive results on effects of TRF on PPAR-γ-LXR-
α- ABCA1/ABCG1 pathway, further studies are warranted.  
Effects of TRF on PPAR-γ, SRA1, CD 36, LXR-α, ABCG1 and ABCA1 obtained in our 
study are summarized in the Figure 4.1. 
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Figure 4.1: Summary of effects observed with TRF (16 µg/ml for 48 hours) PPAR-γ 
and its downstream efflux and influx genes in J774A.1 macrophages  
TRF and placebo treatments used in this study were prepared from commercially available 
capsules and both contained wheat germ oil. In contrast to placebo, TRF contained 74.68% 
tocotrienols and 23.5% tocopherol per capsule (61.01 mg of tocopherols and 198.56 mg of 
tocotrienols; total amount 260.17 mg). In fact, effects of TRF on these genes were observed 
with ~1.6x 104 diluted solution (16 µg/ml) of original TRF-2 capsule (260.17 mg/ml). More 
importantly, significant changes of gene expression observed in the study are seen only 
with TRF treatment and placebo treatment did not cause any significant changes.  
Therefore, the results obtained from the study can be attributed to effects of TRF. 
This is further supported by the pre-clinical study conducted by our lab [49]. In this study 
hemodialysis patients were supplied with 2 capsules of TRF-1 or placebo, 3 times a week 
for 16 weeks. TRF group caused a significant increase in plasma HDL at both 12th week 
and 16th week compared to placebo group. Similarly, TRF treatment increased plasma Apo 
A1 levels and decreased plasma TG level compared to placebo at week 12. Furthermore, 
TRF 
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TRF treatment increased CETP activity in both 12th and 16th week compared to placebo 
indicating potential beneficial effects of TRF. 
However, TRF used in this study (TRF-2) contained 23.5 % of α-tocopherol in addition to 
74.68% of tocotrienols. Several research articles suggest that tocotrienols have superior 
activity over tocopherol. In the study by Li et al, where significant increase in PPAR-γ in 
THP-1macrophages was observed with 24 hour treatment, 25 µM of α-tocopherol did not 
caused significant change in PPAR-γ and LXR-α [54]. Furthermore, superior action of TRF 
over tocopherols is reported in related to anti-oxidant [40, 41, 66-68], anti-inflammatory 
[69], anti-cancer [70-72], hypocholesterolemic [73, 74] and neuroprotective [75] 
properties. These finding suggest that, PPAR-γ agonistic effects observed in our study can 
be attributed to tocotrienols present in TRF. However, to conclude this, further studies are 
warranted with pure tocotrienols and tocopherol isomers. 
Based on the results of cholesterol efflux gene expression study, it can be postulated that 
TRF may have potential PPAR-γ agonistic effects, that can increase net cholesterol efflux. 
However, to further conclude the gene expression data, further experiments that evaluate 
time and dose dependent effects of TRF on protein expression of these receptors are 
warranted. More importantly, a cholesterol efflux assay has to be conducted to understand 
the overall effect of TRF on cholesterol efflux. In addition, selectively over expressing and 
inhibiting each influx and efflux gene in-vitro and assessing effects of TRF on their gene 
expression, protein expression and their contribution to cholesterol efflux may further help 
understand the targeted effect of TRF on the unique role played by each protein. 
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CHAPTER 5: Conclusion 
Tocotrienols are naturally occurring bioactive compounds which possess anti-atherogenic 
and anti-cancer properties.  In our pilot study with ESRD patients, TRF supplementation 
increased HDL, Apo-A1 and reduced CETP level, all which participate in latter steps of 
RCT. As a preliminary study of identifying potential benefits of TRF which will be given 
to ESRD patients in our multi-centered clinical intervention study, this study was designed 
to identify the anti-cancer properties of TRF and to explore the effects of TRF on 
cholesterol efflux, which is an early step of RCT. New TRF (TRF 2 and 3) significantly 
inhibited NSCLC cell growth indicating contents in TRF capsules are active. It further 
supported that new TRF have anti-cancer properties on NSCLC, whereas placebo did not. 
In addition, results suggest that TRF-2 acts as a potential PPAR-γ agonist, which may 
promote cholesterol efflux. Increased expression of PPAR-γ due to TRF-2 may cause no 
net uptake of cholesterol into macrophages through increasing CD36 gene and decreasing 
SRA1 genes. Further, TRF-2 increased the expression of SRB1 which may promote SRB1-
mediated cholesterol efflux. Therefore, as a collective effect, TRF-2 may increase net 
cholesterol efflux. Taken together, data from this study suggest that TRF-2 which have a 
similar composition to TRF that will be given to ESRD patients, have potential anti-cancer 
effects and also may favor an increase in cholesterol efflux, reflecting its potential 
atheroprotective properties. 
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Tocotrienols are naturally occurring bioactive compounds which possess beneficial effects 
on multiple chronic diseases including atherosclerosis and cancer. It is believed to exert 
atheroprotective effects via promoting reverse cholesterol transport, a process that removes 
excess cholesterol from the body. Cholesterol efflux is an early step in reverse cholesterol 
transport and impaired cholesterol efflux is known to trigger foam cell formation, a 
hallmark of atherosclerosis. An increase in cholesterol efflux and decrease in cholesterol 
influx in macrophages has been suggested to reduce atherosclerosis risk by reducing foam 
cell formation. In addition, tocotrienols have shown anti-cancer effects on Non-small cell 
lung cancer (NSCLC). Therefore, the objective of this study was to investigate time and 
dose dependent effects of Tocotrienols Rich Fraction (TRF) derived from Palm oil (74.68% 
63 
 
 
 
Tocotrienols and 23.5% Tocopherols) on PPAR-γ, a key modulator of cholesterol efflux, 
its downstream cholesterol influx (SRA1, CD 36) and genes related to efflux (LXR-α, 
ABCA1, ABCG1, SRB1) in J774A.1 macrophages. To confirm contents of TRF capsules 
are active, anti-cancer effects of TRF on NSCLC cell lines were used. Effects of three TRF 
batches (TRF 1, TRF 2 and TRF 3) on A549 cell proliferation were determined using MTS 
assay (0,40,80,120 µg/ml). Western-blot analysis was used to test the effects of TRF 1 on 
Notch-1 expression, a protein involved in cancer cell proliferation. All three different 
batches significantly reduced A549 cell growth, starting from 80 µg/ml and TRF -1 dose 
dependently decreased Notch-1 protein expression.   Non-toxic concentrations range of 
TRF-2 for J774A.1 cells were determined using MTS assay and the effect of TRF-2 on 
PPAR-γ, influx and efflux genes were explored using real-time PCR. Based on MTS assay 
results, concentrations of 0, 8, 16 µg/ml of TRF-2 were selected for 24 and 48 hour 
treatments for J774A.1 cells. According to PCR data, treatment with 16 µg/ml TRF-2 for 
48 hours showed the highest significant increase of PPAR-γ, SRB1, and CD 36 expression, 
and the highest significant decrease in SRA1 and ABCA1 expression compared to the 
control under tested conditions. At these conditions, both LXR- α and ABCG1 were not 
significantly changed. Taken together, our data suggests that TRF impacts both influx and 
efflux genes via upregulation of PPAR-γ, such that the net effect favors increase in 
cholesterol efflux. 
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